Given that OC attenuates PAR-2 expression, it is plausible to hypothesize that it may concurrently modulate the activity or expression of these efflux transporters, potentially enhancing the intracellular retention and efficacy of anti-cancer agents. The gene discussed is F2RL1; the disease is cancer.